Skip to main content
Mylan, Revance enter licensing deal on Botox biosimilar
3/1/2018

Mylan and Revance Therapeutics agreed to work together to develop a biosimilar of Allergan's Botox, which is indicated for the treatment of wrinkles. Under the deal, Revance will receive an upfront payment of $25 million.

Full Story: